Bridging the implementation gap in medication adherence. If you build it, will they come?

Affiliations

Comment

Jane S Hankins et al. Br J Haematol. 2022 Jan.

. 2022 Jan;196(1):17-18.

doi: 10.1111/bjh.17953. Epub 2021 Nov 16.

No abstract available

Keywords: Dissemination and Implementation Research; implementation science; medication adherence; medication compliance; sickle cell disease.

Comment on

A randomised controlled provider-blinded trial of community health workers in sickle cell anaemia: effects on haematologic variables and hydroxyurea adherence.
Smith WR, McClish DK, Lottenberg R, Sisler IY, Sop D, Johnson S, Villella A, Liles D, Yang E, Chen I. Smith WR, et al. Br J Haematol. 2022 Jan;196(1):193-203. doi: 10.1111/bjh.17952. Epub 2021 Nov 16. Br J Haematol. 2022. PMID: 34786695 Clinical Trial.

1. Konstantinou P, Kassianos AP, Georgiou G, Panayides A, Papageorgiou A, Almas I, et al. Barriers, facilitators, and interventions for medication adherence across chronic conditions with the highest non-adherence rates: a scoping review with recommendations for intervention development. Transl Behav Med. 2020;10:1390-8.
1. Shih S, Cohen LL. A Systematic review of medication adherence interventions in pediatric sickle cell disease. J Pediatr Psychol. 2020;45:593-606.
1. Qureshi A, Kaya B, Pancham S, Keenan R, Anderson J, Akanni M, et al. Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease: a British Society for Haematology Guideline. Br J Haematol. 2018;181:460-75.
1. Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033-48.
1. Kayle M, Valle J, Paulukonis S, Holl JL, Tanabe P, French DD, et al. Impact of Medicaid expansion on access and healthcare among individuals with sickle cell disease. Pediatr Blood Cancer. 2020;67:e28152.